Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Receivables: 2022-2024

Historic Change in Receivables for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Dec 2024 value amounting to -$39.6 million.

  • Amylyx Pharmaceuticals' Change in Receivables rose 101.27% to $30,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year increase of 94.21%. This contributed to the annual value of -$39.6 million for FY2024, which is 260.05% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Change in Receivables stood at -$39.6 million, which was down 260.05% from $24.7 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Receivables ranged from a high of $24.7 million in FY2023 and a low of -$39.6 million during FY2024.
  • Its 3-year average for Change in Receivables is $149,333, with a median of $15.3 million in 2022.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Change in Receivables surged by 61.66% in 2023, and later slumped by 260.05% in 2024.
  • Amylyx Pharmaceuticals' Change in Receivables (Yearly) stood at $15.3 million in 2022, then surged by 61.66% to $24.7 million in 2023, then crashed by 260.05% to -$39.6 million in 2024.